Andrew K. Godwin
Works at
University of Kansas Medical Center
Associate director
Sources: reporter.nih.gov
Grants and prizes
R01, Intercepting Ovarian Cancer at Its Earliest Stage: Validation of Tu-Stroma as a Blood-Based Diagnostic Biomarker, R01CA318082, 2026–2031, 3 Sept 2026
R01, Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem, R01CA260132, 2021–2026, 19 Mar 2025
Sources: reporter.nih.gov